JP2017503016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503016A5 JP2017503016A5 JP2016560857A JP2016560857A JP2017503016A5 JP 2017503016 A5 JP2017503016 A5 JP 2017503016A5 JP 2016560857 A JP2016560857 A JP 2016560857A JP 2016560857 A JP2016560857 A JP 2016560857A JP 2017503016 A5 JP2017503016 A5 JP 2017503016A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- diffractometer
- determined
- powder
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MZBLZLWXUBZHSL-FZNJKFJKSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@](C3)([C@@H]3C(F)F)C(NS(C3(C)CC3)(=O)=O)=O)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@](C3)([C@@H]3C(F)F)C(NS(C3(C)CC3)(=O)=O)=O)=O)N1C2=O MZBLZLWXUBZHSL-FZNJKFJKSA-N 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920427P | 2013-12-23 | 2013-12-23 | |
| US61/920,427 | 2013-12-23 | ||
| PCT/US2014/071310 WO2015100144A1 (en) | 2013-12-23 | 2014-12-18 | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019020540A Division JP2019089819A (ja) | 2013-12-23 | 2019-02-07 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503016A JP2017503016A (ja) | 2017-01-26 |
| JP2017503016A5 true JP2017503016A5 (enExample) | 2018-01-18 |
| JP6568541B2 JP6568541B2 (ja) | 2019-08-28 |
Family
ID=52282995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560857A Expired - Fee Related JP6568541B2 (ja) | 2013-12-23 | 2014-12-18 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
| JP2019020540A Pending JP2019089819A (ja) | 2013-12-23 | 2019-02-07 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019020540A Pending JP2019089819A (ja) | 2013-12-23 | 2019-02-07 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9562058B2 (enExample) |
| EP (1) | EP3087086B1 (enExample) |
| JP (2) | JP6568541B2 (enExample) |
| AR (1) | AR098958A1 (enExample) |
| AU (1) | AU2014370124A1 (enExample) |
| CA (1) | CA2934049A1 (enExample) |
| ES (1) | ES2708993T3 (enExample) |
| NZ (1) | NZ720887A (enExample) |
| PT (1) | PT3087086T (enExample) |
| TW (1) | TW201609752A (enExample) |
| UY (1) | UY35918A (enExample) |
| WO (1) | WO2015100144A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9440991B2 (en) | 2013-12-23 | 2016-09-13 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| CN115417803B (zh) * | 2022-08-30 | 2023-10-03 | 四川同晟生物医药有限公司 | 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| SI2310095T1 (sl) * | 2008-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji |
| DK2618831T3 (en) * | 2010-09-21 | 2016-04-04 | Enanta Pharm Inc | Macrocyclic prolinafledte HCV serine protease inhibitors |
| US20130178413A1 (en) * | 2010-09-21 | 2013-07-11 | John A. McCauley | Hcv ns3 protease inhibitors |
| UA110354C2 (uk) | 2011-11-16 | 2015-12-25 | Гайлід Фармассет Елелсі | Противірусні сполуки |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
-
2014
- 2014-12-18 WO PCT/US2014/071310 patent/WO2015100144A1/en not_active Ceased
- 2014-12-18 ES ES14824322T patent/ES2708993T3/es active Active
- 2014-12-18 US US14/575,966 patent/US9562058B2/en active Active
- 2014-12-18 EP EP14824322.3A patent/EP3087086B1/en active Active
- 2014-12-18 CA CA2934049A patent/CA2934049A1/en not_active Abandoned
- 2014-12-18 PT PT14824322T patent/PT3087086T/pt unknown
- 2014-12-18 JP JP2016560857A patent/JP6568541B2/ja not_active Expired - Fee Related
- 2014-12-18 AU AU2014370124A patent/AU2014370124A1/en not_active Abandoned
- 2014-12-18 NZ NZ720887A patent/NZ720887A/en not_active IP Right Cessation
- 2014-12-22 TW TW103144805A patent/TW201609752A/zh unknown
- 2014-12-23 UY UY0001035918A patent/UY35918A/es not_active Application Discontinuation
- 2014-12-23 AR ARP140104909A patent/AR098958A1/es unknown
-
2016
- 2016-12-21 US US15/387,318 patent/US9862728B2/en active Active
-
2019
- 2019-02-07 JP JP2019020540A patent/JP2019089819A/ja active Pending